Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Zanco Journal of Medical Sciences. 2016; 20 (2): 1356-1360
in English | IMEMR | ID: emr-184517

ABSTRACT

Background and objective: Controlling medications safely, effectively and efficiently is essential to the delivery of high-quality care. This study aimed to point up prescription errors such as scientific or brand names, the strength of medications, the age of patients, date of prescriptions, specifying dose, dose interval, dosing frequency and dosage form, through systematic studying a certain number of prescriptions


Methods: This study screened the prescriptions from both of public and private sectors in the governorates of Erbil, Sulaimaniyah and Duhok. Adherence was assessed on the basis of these prescriptions charts. Excel program was utilized to evaluate the data in this study


Results: The study covered a total 283 prescriptions involving 976 medications in Kurdistan region. Only 19% of medications were mentioned as a scientific name and just 2% of prescriptions were written via computer. Direction for use of the medicines was only mentioned for 3% and the duration of treatment was scripted in 11%


Conclusion: Majority of medical practitioners in Kurdistan region are not adhering to the international standards of prescriptions

2.
Zanco Journal of Medical Sciences. 2016; 20 (2): 1385-1389
in English | IMEMR | ID: emr-184521

ABSTRACT

Background and objective: Benign prostatic hyperplasia involves the enlargement of prostatic glandular tissue and narrowing of the urethra. It affects bladder storage or emptying. Most of the men with benign prostatic hyperplasia have no symptoms. This study aimed to compare international prostate symptom scores, prostate specific antigen level and prostate volume in patients having benign prostatic hyperplasia with and without metabolic syndrome


Methods: This study involved 85 patients with benign prostatic hyperplasia who were divided into two groups. The first group included 40 participants who were only suffering from benign prostatic hyperplasia and the second group involved 45 participants who were suffering from both metabolic syndrome and benign prostatic hyperplasia. The division of subjects was performed depending on three abnormal parameters out of five parameters, such as body mass index [BMI >25kg/m2], dyslipidemia [Triglyceride >/=150 mg/dl, High density lipoprotein-C <40 mg/dl], blood pressure [BP >/=130/85 mmHg], fasting plasma glucose [PG >/=110 mg/dl]


Results: Patients with metabolic syndrome at diagnosis appears to have significantly higher levels of prostate specific antigen comparing with patients without metabolic syndrome, 3.9+/-0.26 and 2.7+/-0.21, respectively. Similarly, patients with metabolic syndrome at diagnosis had significantly higher prostate volume levels [72.69 +/- 2.69 ml] comparing to patients without metabolic syndrome [46 +/- 2.44 ml]. Patients with metabolic syndrome at diagnosis showed considerable higher international prostate symptom scores level [23.62 +/- 0.62] compared to patients without metabolic syndrome [18.87 +/- 0.327]


Conclusions: benign prostatic hyperplasia patients having metabolic syndrome have significantly higher values of prostate specific antigen levels, prostate volume and international prostate symptom scores compared to benign prostate hyperplasia patients without metabolic syndrome

SELECTION OF CITATIONS
SEARCH DETAIL